Adicet announces appointment of dr. bastiano sanna to its board of directors

Menlo park, calif. and boston, dec. 01, 2020 (globe newswire) -- adicet bio, inc. (nasdaq: acet), a biotechnology company discovering and developing first-in-class allogeneic gamma delta t cell therapies for cancer and other diseases, today announced the appointment of bastiano sanna, ph.d., to its board of directors. dr. sanna brings significant expertise in advancing research, development and manufacturing of cell therapies. he currently serves as executive vice president and chief of cell and genetic therapies at vertex pharmaceuticals incorporated.
ACET Ratings Summary
ACET Quant Ranking